According to research presented at the EAHAD 2024 Annual Congress, a new classification system enhances diagnosis and ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

The government has set aside £11.8bn to compensate victims of the infected blood scandal, after a public inquiry found the ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

New Delhi, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The global hemophilia treatment market is set for significant growth, with revenues expected to rise from USD 13.23 billion in 2024 to USD 21.48 ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

Hemophilia B is a genetic condition that limits your blood’s ability to clot. Without prompt treatment, it can become a life threatening emergency. Creating a plan can help you better manage ...

The Balochistan government has introduced free treatment for breast cancer, Hemophilia A, Multiple Sclerosis, and Juvenile ...

Researchers at E-Therapeutics plc recently presented efficacy and safety data on ETX-148, a pan-hemophilia agent in murine models of hemophilia A and B.

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...